| 书目名称 | Renal Anemia |
| 副标题 | Conflicts and Contro |
| 编辑 | Onyekachi Ifudu (Associate Professor of Medicine, |
| 视频video | http://file.papertrans.cn/827/826976/826976.mp4 |
| 图书封面 |  |
| 描述 | Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management. |
| 出版日期 | Book 2002 |
| 关键词 | anemia; erythropoietin; kidney; nephrology; sepsis; diabetes |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-94-015-9998-6 |
| isbn_softcover | 978-90-481-6045-7 |
| isbn_ebook | 978-94-015-9998-6 |
| copyright | Springer Science+Business Media Dordrecht 2002 |
|Archiver|手机版|小黑屋|
派博传思国际
( 京公网安备110108008328)
GMT+8, 2025-7-15 22:37
发表于 2025-3-21 19:37:31
